Space Pharmacology: How Space Affects Pharmacology

  • Virginia WotringEmail author
Living reference work entry


The spaceflight environment is at best, very different from Earth, and at worst (without the protection offered by the systems of a space suit or a spacecraft) deadly. Candidates for NASA’s astronaut program must meet many requirements to be selected, but even the healthiest people in the best circumstances use medications from time to time. During their spaceflight missions, astronauts are exposed to perhaps the most extreme of all extreme environments, and there are features of the spaceflight environment that drive uses of particular medications. This chapter will provide an overview of these mission-related medication needs and will discuss the special considerations that must be given to stocking the medication supplies for use on spaceflight missions.

References and Further Reading

  1. Ahlstrand C, Tiselius HG (1987) Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 21(3):225–228CrossRefPubMedGoogle Scholar
  2. Alhnan MA, Okwuosa TC, Sadia M, Wan KW, Ahmed W, Arafat B (2016) Emergence of 3D printed dosage forms: opportunities and challenges. Pharm Res 33(8):1817–1832. Scholar
  3. Arendt J, Van Someren EJ, Appleton R, Skene DJ, Akerstedt T (2008) Clinical update: melatonin and sleep disorders. Clin Med 8(4):381–383CrossRefGoogle Scholar
  4. Armaghani SJ, Crucian GP, Heilman KM (2014) The influence of emotional faces on the spatial allocation of attention. Brain Cogn 91:108–112. Scholar
  5. Barger LK, Flynn-Evans EE, Kubey A, Walsh L, Ronda JM, Wang W, Wright KP Jr, Czeisler CA (2014) Prevalence of sleep deficiency and use of hypnotic drugs in astronauts before, during, and after spaceflight: an observational study. Lancet Neurol 13(9):904–912. Scholar
  6. Carpentier W, Charles JB, Shelhamer M, Hackler AS, Johnson TL, Domingo CMM, GBI S, Wotring VE (2018) Biomedical findings from NASA’s project mercury: a case series. npj Microgravity 4(6).
  7. Chancellor JC, Scott GB, Sutton JP (2014) Space radiation: the number one risk to astronaut health beyond low earth orbit. Life (Basel) 4(3):491–510. Scholar
  8. Cintrón NM, Putcha L, Chen Y-M, Vanderploeg JM (eds) (1987) In-flight salivary pharmacokinetics of scopolamine and dextroamphetamine. In: Results of the life sciences DSOs conducted aboard the space shuttle 1981–1986. Space Biomedical Research Institute, Johnson Space Center, HoustonGoogle Scholar
  9. Crucian B, Johnston S, Mehta S, Stowe R, Uchakin P, Quiriarte H, Pierson D, Laudenslager ML, Sams C (2016) A case of persistent skin rash and rhinitis with immune system dysregulation onboard the international Space Station. J Allergy Clin Immunol Pract 4(4):759–762., e758. Scholar
  10. Cucinotta FA, Kim MHY, Chapell LJ (2010) Space radiation cancer risk projections and uncertainties – 2010. vol TP-2011-216155 NASA TP-2011-216155. NASA Center for AeroSpace Information, HanoverGoogle Scholar
  11. Davis JR, Vanderploeg JM, Santy PA, Jennings RT, Stewart DF (1988) Space motion sickness during 24 flights of the space shuttle. Aviat Space Environ Med 59(12):1185–1189PubMedGoogle Scholar
  12. Dijk DJ, Neri DF, Wyatt JK, Ronda JM, Riel E, Ritz-De Cecco A, Hughes RJ, Elliott AR, Prisk GK, West JB, Czeisler CA (2001) Sleep, performance, circadian rhythms, and light-dark cycles during two space shuttle flights. Am J Phys Regul Integr Comp Phys 281(5):R1647–R1664Google Scholar
  13. Du B, Daniels V, Vaksman Z, Boyd J, Crady C, Putcha L (2011) Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. AAPS J 13(2):299–308CrossRefPubMedPubMedCentralGoogle Scholar
  14. Estrada A, Kelley AM, Webb CM, Athy JR, Crowley JS (2012) Modafinil as a replacement for dextroamphetamine for sustaining alertness in military helicopter pilots. Aviat Space Environ Med 83(6):556–564CrossRefPubMedGoogle Scholar
  15. FDA (2017) CDER researchers explore the promise and potential of 3D printed pharmaceuticals. Food and Drug Adminstration Accessed 4 Apr 2018
  16. Flynn-Evans EE, Barger LK, Kubey AA, Sullivan JP, Czeisler CA (2016) Circadian misalignment affects sleep and medication use before and during spaceflight. npj Microgravity 2.
  17. Fond G, Micoulaud-Franchi JA, Brunel L, Macgregor A, Miot S, Lopez R, Richieri R, Abbar M, Lancon C, Repantis D (2015) Innovative mechanisms of action for pharmaceutical cognitive enhancement: a systematic review. Psychiatry Res 229(1–2):12–20. Scholar
  18. Fucci RL, Gardner J, Hanifin JP, Jasser S, Byrne B, Gerner E, Rollag M, Brainard GC (2005) Toward optimizing lighting as a countermeasure to sleep and circadian disruption in space flight. Acta Astronaut 56(9–12):1017–1024CrossRefPubMedGoogle Scholar
  19. Goel N, Dinges DF (2012) Predicting risk in space: genetic markers for differential vulnerability to sleep restriction. Acta Astronaut 77:207–213. Scholar
  20. Hershkovitz D, Asna N, Shupak A, Kaminski G, Bar R, Tal D (2009) Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Aviat Space Environ Med 80(7):643–646CrossRefPubMedGoogle Scholar
  21. Homick JL (1979) Space motion sickness. Acta Astronaut 6(10):1259–1272CrossRefPubMedGoogle Scholar
  22. Hu S, Kim MH, McClellan GE, Cucinotta FA (2009) Modeling the acute health effects of astronauts from exposure to large solar particle events. Health Phys 96(4):465–476. Scholar
  23. Jennings RT (1998) Managing space motion sickness. J Vestib Res 8(1):67–70. Scholar
  24. Johnston S (2010) Operational ground testing protocol to optimize astronaut sleep medication efficacy and individual effects. Accessed 4/3/2018
  25. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the slone survey. JAMA 287(3):337–344CrossRefPubMedGoogle Scholar
  26. Keasling JD (2010) Manufacturing molecules through metabolic engineering. Science 330(6009):1355–1358. Scholar
  27. Kovachevich I, Kondratenko S, Starodubtsev AK, Repenkova LG (2009) Pharmacokinetics of acetaminophen administered in tablets and capsules under long-term space flight conditions. Pharm Chem J 43(3):130–133CrossRefGoogle Scholar
  28. Law J, Van Baalen M, Foy M, Mason SS, Mendez C, Wear ML, Meyers VE, Alexander D (2014) Relationship between carbon dioxide levels and reported headaches on the international space station. J Occup Environ Med 56(5):477–483. Scholar
  29. Lawley JS, Petersen LG, Howden EJ, Sarma S, Cornwell WK, Zhang R, Whitworth LA, Williams MA, Levine BD (2017) Effect of gravity and microgravity on intracranial pressure. J Physiol 595(6):2115. Scholar
  30. LeBlanc A, Matsumoto T, Jones J, Shapiro J, Lang T, Shackelford L, Smith SM, Evans H, Spector E, Ploutz-Snyder R, Sibonga J, Keyak J, Nakamura T, Kohri K, Ohshima H (2013) Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight. Osteoporos Int 24(7):2105–2114. Scholar
  31. Lee AG, Mader TH, Gibson CR, Brunstetter TJ, Tarver WJ (2018) Space flight-associated neuro-ocular syndrome (SANS). Eye (Lond).
  32. Lockley SW, Brainard GC, Czeisler CA (2003) High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. J Clin Endocrinol Metab 88(9):4502–4505. Scholar
  33. Mader TH, Gibson CR, Pass AF, Kramer LA, Lee AG, Fogarty J, Tarver WJ, Dervay JP, Hamilton DR, Sargsyan A, Phillips JL, Tran D, Lipsky W, Choi J, Stern C, Kuyumjian R, Polk JD (2011) Optic disc edema, globe flattening, choroidal folds, and hyperopic shifts observed in astronauts after long-duration space flight. Ophthalmology 118(10):2058–2069. Scholar
  34. Minard CG, de Carvalho MF, Iyengar MS (2011) Optimizing medical resources for spaceflight using the integrated medical model. Aviat Space Environ Med 82(9):890–894CrossRefPubMedGoogle Scholar
  35. Oman CM (1998) Sensory conflict theory and space sickness: our changing perspective. J Vestib Res 8(1):51–56CrossRefPubMedGoogle Scholar
  36. Putcha L (2009) Data mining – pharmacotherapeutics of space motion sicknessGoogle Scholar
  37. Putcha L, Berens KL, Marshburn TH, Ortega HJ, Billica RD (1999) Pharmaceutical use by U.S. astronauts on space shuttle missions. Aviat Space Environ Med 70(7):705–708PubMedGoogle Scholar
  38. Putcha L, Taylor P, Daniels V, Pool S (2016) Clinical pharmacology and therapeutics. In: Nicogossian AE (ed) Space physiology and medicine: from evidence to practice, 4th edn. Springer, New York p 323Google Scholar
  39. Shende C, Smith W, Brouillette C, Farquharson S (2014) Drug stability analysis by Raman spectroscopy. Pharmaceutics 6(4):651–662. Scholar
  40. Smith SM, Zwart SR (2008) Nutritional biochemistry of spaceflight. Adv Clin Chem 46:87–130CrossRefPubMedGoogle Scholar
  41. Smith SM, Heer MA, Shackelford LC, Sibonga JD, Ploutz-Snyder L, Zwart SR (2012) Benefits for bone from resistance exercise and nutrition in long-duration spaceflight: evidence from biochemistry and densitometry. J Bone Miner Res 27(9):1896–1906. Scholar
  42. Stingl JC, Welker S, Hartmann G, Damann V, Gerzer R (2015) Where failure is not an option -personalized medicine in astronauts. PLoS One 10(10):e0140764. Scholar
  43. Stuster JW (1996) Bold endeavors: behavioral lessons from polar and space exploration. Naval Institute Press, AnnapolisGoogle Scholar
  44. Thornton WE (2011) A rationale for space motion sickness. Aviat Space Environ Med 82(4):467–468CrossRefPubMedGoogle Scholar
  45. Watkins S, Barr Y, Kerstman E (2011) The space medicine exploration medical conditions list. In: 18th IAA humans in space symposium. IAA, HoustonGoogle Scholar
  46. WHO (2017) World health organization model list of essential medicines. Accessed 4 Apr 2018, 20th list
  47. Wilson JW (2000) Overview of radiation environments and human exposures. Health Phys 79(5):470–494CrossRefPubMedGoogle Scholar
  48. Wotring VE (2010) Evidence Book: Pharmacology Risk Report National Aeronautics and Space Administration, HRP-47060, Lyndon B. Johnson Space Center Houston, TexasGoogle Scholar
  49. Wotring VE (2012) Space pharmacology. Springer briefs in space development. Springer, New YorkGoogle Scholar
  50. Wotring V (2015a) Dose tracker application for monitoring medication usage, symptoms, and adverse effects during missions. NASA Johnson Space Center. Accessed 4 Apr 2018
  51. Wotring VE (2015b) Medication use by U.S. crewmembers on the international Space Station. FASEB J 29(11):4417–4423. Scholar
  52. Wotring VE (2016) Chemical potency and degradation products of medications stored over 550 earth days at the international space station. AAPS J 18(1):210–216. Scholar
  53. Zeitlin C, Hassler DM, Cucinotta FA, Ehresmann B, Wimmer-Schweingruber RF, Brinza DE, Kang S, Weigle G, Bottcher S, Bohm E, Burmeister S, Guo J, Kohler J, Martin C, Posner A, Rafkin S, Reitz G (2013) Measurements of energetic particle radiation in transit to Mars on the Mars science laboratory. Science 340(6136):1080–1084. Scholar
  54. Zhang LF, Hargens AR (2018) Spaceflight-induced intracranial hypertension and visual impairment: pathophysiology and countermeasures. Physiol Rev 98(1):59–87. Scholar
  55. Zoldak JT (2016) Medical consumables tracking. NASA Johnson Space Center Accessed 4 Apr 2018
  56. Zwart SR, Launius RD, Coen GK, Morgan JL, Charles JB, Smith SM (2014) Body mass changes during long-duration spaceflight. Aviat Space Environ Med 85(9):897–904. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Center for Space Medicine and Department of Pharmacology and Chemical BiologyBaylor College of MedicineHoustonUSA

Personalised recommendations